Mapping the whole-body biodistribution of lipid nanoparticle (LNP) encapsulated mRNA therapeutics is fundamental to linking pharmacokinetic (PK) exposure with pharmacodynamic (PD) response and safety. In vivo imaging systems (IVIS) provide a non-invasive, longitudinal method to visualize and quantify reporter gene expression, offering real-time insights into delivery efficiency and tissue tropism. This approach complements terminal, quantitative methods like qPCR and histology, enabling a more comprehensive understanding of an asset’s in vivo behavior to de-risk development and support an accelerated path to IND.
What is the primary advantage of using IVIS for LNP-mRNA biodistribution?
The key advantage is the ability to perform non-invasive, longitudinal tracking of reporter protein expression within the same animal cohort over time. This reduces biological variability and the total number of animals required, directly supporting the 3Rs principles of animal welfare. It provides a dynamic view of expression kinetics from onset to peak and through clearance.
How does IVIS imaging complement traditional biodistribution methods like qPCR or histology?
IVIS provides a macro-level, semi-quantitative visualization of whole-body distribution, identifying primary and secondary sites of protein expression. It serves as a powerful screening tool to guide terminal studies. Methods like qPCR and histology then provide highly sensitive, quantitative data on mRNA copies or protein presence within specific tissues collected at pre-defined endpoints. The methods are highly complementary.
Can IVIS differentiate between the LNP carrier and the mRNA payload?
Yes, through a dual-labeling strategy. The LNP can be tagged with a fluorescent lipophilic dye for optical imaging, while the mRNA payload encodes a bioluminescent reporter like luciferase. This allows for concurrent imaging to determine if the LNP delivery vehicle and the functional mRNA payload are co-localizing as intended.
What is the typical study duration for an LNP-mRNA IVIS biodistribution study?
Study duration is tailored to the specific therapeutic’s expected expression profile. A typical study can range from 24 hours to 7-10 days, with imaging performed at multiple time points (e.g., 6, 24, 48, 72 hours post-dose) to capture the complete expression and clearance curve.
